Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

RMD

Resmed Inc.

May 21 • 11:22AM ET

218.65

Dollar change -0.09
Percentage change -0.04	%

Healthcare • Medical Instruments & Supplies • USA • NYSE

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO VO IVV VUG VOT IHI VIG IWP RSP

Index	S&P 500	P/E	33.65	EPS (ttm)	6.50	Insider Own	0.80%	Shs Outstand	147.06M	Perf Week	1.30%
Market Cap	32.12B	Forward P/E	24.96	EPS next Y	8.76	Insider Trans	-4.49%	Shs Float	145.80M	Perf Month	21.23%
Income	958.38M	PEG	2.59	EPS next Q	2.08	Inst Own	58.27%	Short Float	6.76%	Perf Quarter	21.27%
Sales	4.58B	P/S	7.01	EPS this Y	19.97%	Inst Trans	-0.38%	Short Ratio	9.00	Perf Half Y	46.80%
Book/sh	31.52	P/B	6.94	EPS next Y	13.37%	ROA	14.17%	Short Interest	9.85M	Perf Year	-2.61%
Cash/sh	1.62	P/C	135.01	EPS next 5Y	13.00%	ROE	22.39%	52W Range	132.24 - 229.97	Perf YTD	27.10%
Dividend Est.	1.95 (0.89%)	P/FCF	29.48	EPS past 5Y	22.66%	ROI	16.63%	52W High	-4.92%	Beta	0.70
Dividend TTM	1.92 (0.88%)	Quick Ratio	1.97	Sales past 5Y	12.58%	Gross Margin	54.74%	52W Low	65.34%	ATR (14)	5.12
Dividend Ex-Date	May 08, 2024	Current Ratio	3.04	EPS Y/Y TTM	10.74%	Oper. Margin	28.12%	RSI (14)	63.56	Volatility	1.84% 2.32%
Employees	10140	Debt/Eq	0.25	Sales Y/Y TTM	14.16%	Profit Margin	20.91%	Recom	1.73	Target Price	219.88
Option/Short	Yes / Yes	LT Debt/Eq	0.24	EPS Q/Q	29.19%	Payout	28.91%	Rel Volume	0.24	Prev Close	218.74
Sales Surprise	1.94%	EPS Surprise	10.51%	Sales Q/Q	7.17%	Earnings	Apr 25 AMC	Avg Volume	1.09M	Price	218.65
SMA20	3.16%	SMA50	10.36%	SMA200	27.10%	Trades		Volume	84,470	Change	-0.04%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-06-24	Resumed	KeyBanc Capital Markets	Overweight	$227
Oct-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$180 → $169
Oct-12-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$273 → $202
Oct-09-23	Upgrade	JP Morgan	Neutral → Overweight	$210 → $170
Sep-29-23	Downgrade	Wolfe Research	Outperform → Peer Perform
Sep-06-23	Upgrade	Needham	Hold → Buy	$180
Sep-05-23	Downgrade	UBS	Buy → Neutral	$265 → $170
Aug-01-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$262 → $284
May-23-23	Initiated	UBS	Buy	$290
Apr-14-23	Initiated	Mizuho	Buy	$255
Jan-17-23	Upgrade	JP Morgan	Neutral → Overweight	$245
Oct-28-22	Downgrade	Citigroup	Buy → Neutral
Oct-20-22	Upgrade	BofA Securities	Neutral → Buy	$245 → $260
Oct-12-22	Initiated	Jefferies	Hold
Sep-08-22	Upgrade	Citigroup	Neutral → Buy
Aug-15-22	Downgrade	CLSA	Buy → Outperform
Aug-12-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$246 → $252
Aug-12-22	Downgrade	JP Morgan	Overweight → Neutral
Aug-12-22	Downgrade	Citigroup	Buy → Neutral
Jun-06-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$233 → $244

Show Previous Ratings

Today 09:30AM	Wall Street Analysts See ResMed (RMD) as a Buy: Should You Invest? (Zacks)
May-20-24 10:47AM	Here's Why Investors Should Buy ResMed (RMD) Stock Now (Zacks)
May-16-24 04:35PM	ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy (GlobeNewswire)
12:00PM	What Makes ResMed (RMD) a New Strong Buy Stock (Zacks)
08:05AM	MatrixCare Joins Health Gorilla's Qualified Health Information Network (QHIN) to Enhance Patient Data Access (GlobeNewswire)
12:45PM	Loading…
May-15-24 12:45PM	Here is Why Growth Investors Should Buy ResMed (RMD) Now (Zacks)
09:45AM	Why ResMed (RMD) is a Top Growth Stock for the Long-Term (Zacks)
May-08-24 10:31AM	Viemed Healthcare, Inc. (NASDAQ:VMD) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-07-24 04:05PM	ResMed Announces Participation in the RBCCM Global Healthcare Conference (GlobeNewswire)
May-03-24 09:43AM	Pulmonx Corporation (NASDAQ:LUNG) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-30-24 01:31PM	ResMed Inc. (NYSE:RMD) Q3 2024 Earnings Call Transcript (Insider Monkey)
09:50AM	Why ResMed (RMD) is a Top Momentum Stock for the Long-Term (Zacks)
Apr-29-24 12:45PM	Looking for a Growth Stock? 3 Reasons Why ResMed (RMD) is a Solid Choice (Zacks)
09:45AM	Here's Why ResMed (RMD) is a Strong Growth Stock (Zacks)
Apr-27-24 01:06AM	Decoding ResMed Inc (RMD): A Strategic SWOT Insight (GuruFocus.com)
04:08PM	Loading…
Apr-26-24 04:08PM	How 'Megatrends' Like Weight-Loss Drugs And Smartwatches Are Bolstering ResMed (Investor's Business Daily) +18.89%
03:57PM	Sector Update: Health Care Stocks Edge Higher Late Afternoon (MT Newswires)
02:12PM	Top Midday Gainers (MT Newswires)
01:48PM	Sector Update: Health Care Stocks Higher in Afternoon Trading (MT Newswires)
12:17PM	Top Stock Movers Now: Alphabet, Newell Brands, Intel, and More (Investopedia)
12:08PM	Why ResMed Stock Is Soaring Today (Motley Fool)
11:45AM	ResMed Stock Jumps After Earnings, Revenue Beats (The Wall Street Journal)
11:35AM	KeyBanc Adjusts Price Target on ResMed to $238 From $227 (MT Newswires)
11:26AM	Analyst Report: ResMed Inc. (Morningstar Research)
11:01AM	Update: ResMed's Fiscal Q3 Non-GAAP Earnings, Revenue Increase; Shares Up Over 17% (MT Newswires)
10:33AM	Jefferies Adjusts Price Target on ResMed to $180 From $164 (MT Newswires)
10:12AM	ResMed Stock Soars After Strong Earnings. Wall Street Thinks It Can Do Even Better. (Barrons.com)
10:00AM	ResMed Soars To Eight-Month High As Quarterly Report Wipes Out Weight-Loss Woes (Investor's Business Daily)
08:58AM	Oppenheimer Adjusts ResMed Price Target to $200 From $205, Maintains Outperform Rating (MT Newswires)
08:47AM	JPMorgan Adjusts Price Target on ResMed to $225 From $198 (MT Newswires)
08:37AM	Loading…
08:37AM	ResMed (RMD) Q3 Earnings Beat Estimates, Margins Expand (Zacks)
08:07AM	Mizuho Adjusts Price Target on ResMed to $220 From $215 (MT Newswires)
07:53AM	Needham Adjusts Price Target on ResMed to $236 From $224 (MT Newswires)
06:39AM	Morgan Stanley Adjusts Price Target on ResMed to $219 From $207 (MT Newswires)
06:33AM	Q3 2024 Resmed Inc Earnings Call (Thomson Reuters StreetEvents)
06:16AM	RBC Adjusts Price Target on ResMed to $200 From $187 (MT Newswires)
03:36AM	ResMed Inc (RMD) Q3 2024 Earnings Call Transcript Highlights: Strong Financial Performance and ... (GuruFocus.com)
Apr-25-24 06:30PM	Compared to Estimates, ResMed (RMD) Q3 Earnings: A Look at Key Metrics (Zacks)
05:43PM	ResMed Inc (RMD) Q3 Fiscal 2024 Earnings: Surpasses Analyst Expectations with Strong Growth (GuruFocus.com)
05:25PM	ResMed (RMD) Q3 Earnings and Revenues Surpass Estimates (Zacks)
04:49PM	ResMed Fiscal Q3 Non-GAAP Earnings, Revenue Increase; Shares Rise After Hours (MT Newswires)
04:22PM	ResMed: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024 (GlobeNewswire)
11:34AM	20 Fastest Growing Health Tech Companies in the World (Insider Monkey)
Apr-22-24 09:16AM	ResMed (RMD) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates (Zacks)
Apr-18-24 04:02PM	How The Weight-Loss Bonanza Prompted A ResMed Sell-Off But Could Soon Drive Shares Higher (Investor's Business Daily)
10:01AM	ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Apr-17-24 06:51PM	Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank (Motley Fool) -5.97%
04:09PM	Eli Lilly Pops After Weight-Loss Drug Succeeds In Highly Anticipated Sleep Apnea Test (Investor's Business Daily)
12:08PM	Eli Lilly's Weight-Loss Treatment Found To Help Those With Sleep Apnea (Investopedia)
09:43AM	Eli Lilly Stock Gains After Study Shows Weight-Loss Drug Combats Sleep Apnea (The Wall Street Journal)
Apr-04-24 04:05PM	ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024 (GlobeNewswire)
Apr-01-24 12:44PM	Here's Why Investors Should Buy ResMed (RMD) Stock Now (Zacks)
Mar-30-24 11:49AM	10 Best Long Term ASX Stocks To Invest In (Insider Monkey)
Mar-15-24 03:05AM	ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis (GlobeNewswire)
Mar-07-24 09:45AM	Nyxoah S.A. (NASDAQ:NYXH) Q4 2023 Earnings Call Transcript (Insider Monkey)
07:33AM	ResMed (RMD) Debuts the Smallest Full-Face CPAP Mask AirFit F40 (Zacks)
Mar-06-24 09:05AM	Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed's Smallest Full-Face CPAP Mask (GlobeNewswire)
Feb-24-24 03:10AM	ResMed Inc Director Peter Farrell Sells 23,535 Shares (GuruFocus.com)
Feb-23-24 11:30AM	Why Is ResMed (RMD) Down 1.7% Since Last Earnings Report? (Zacks)
Feb-22-24 09:53AM	Got $1,000? Buy These Hot Growth Stocks Before They Take Off (Motley Fool)
Feb-20-24 01:35PM	Here's Why Investors Should Retain ResMed (RMD) Stock for Now (Zacks)
Feb-18-24 01:26PM	25 Most Valuable Medical Device Companies in the US (Insider Monkey)
Feb-16-24 10:26AM	ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 (Revised) (Zacks)
10:00AM	Jerry McGinnis, a Pioneer of Sleep Medicine, Dies at Age 89 (The Wall Street Journal)
Feb-13-24 10:23AM	ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 Device (Zacks)
Feb-12-24 04:16PM	ResMed's New AirCurve 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea (GlobeNewswire)
Feb-07-24 08:05AM	MatrixCare Earns Three 2024 Best in KLAS Awards (GlobeNewswire)
Feb-05-24 09:45AM	Why ResMed (RMD) is a Top Growth Stock for the Long-Term (Zacks)
Jan-29-24 04:09PM	Three-Stock Lunch: SoFi, Warner Bros. Discovery and ResMed (CNBC TV)
10:56AM	MatrixCare Forges Strategic Partnership with Tranzion, a Subsidiary of NHC, to Expand EHR Services for Senior Living Medical Providers (GlobeNewswire)
12:30AM	ResMed CEO: Weight-Loss Drugs Arent Cutting Demand for Sleep Apnea Treatment (Barrons.com)
Jan-26-24 09:15PM	Analyst Report: ResMed Inc. (Morningstar Research)
09:50AM	Here's Why ResMed (RMD) is a Strong Momentum Stock (Zacks)
12:12AM	Decoding ResMed Inc (RMD): A Strategic SWOT Insight (GuruFocus.com)
Jan-25-24 04:05PM	ResMed Surges And Retakes A Key Line As The Battle With Weight-Loss Drugs Rages (Investor's Business Daily) +8.48%
12:38PM	Q2 2024 Resmed Inc Earnings Call (Thomson Reuters StreetEvents)
12:07PM	Why ResMed Stock Is Jumping Today (Motley Fool)
12:04PM	ResMed (RMD) Q2 Earnings Beat Estimates, Margins Expand (Zacks)
11:03AM	ResMed Inc. (NYSE:RMD) Q2 2024 Earnings Call Transcript (Insider Monkey)
10:33AM	ResMed Surges But Hits A Ceiling As The Battle With Weight-Loss Drugs Rages (Investor's Business Daily)
09:03AM	ResMed Flexes Its Operating Muscle, Sends Shares Flying Above Their 200-Day Line (Investor's Business Daily)
06:12AM	Analyst Report: ResMed Inc. (Morningstar Research)
Jan-24-24 07:00PM	ResMed (RMD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:07PM	ResMed beats estimates on strong sleep apnea device sales (Reuters)
05:25PM	ResMed (RMD) Tops Q2 Earnings and Revenue Estimates (Zacks)
05:22PM	REFILE-ResMed beats estimates on strong sleep apnea device sales (Reuters)
04:43PM	ResMed Inc (RMD) Reports Solid Revenue Growth in Q2 FY2024 Amidst Expanding Global Market Presence (GuruFocus.com)
04:27PM	ResMed: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024 (GlobeNewswire)
Jan-23-24 10:29AM	Hedge Fund and Insider Trading News: Brevan Howard Asset Management, Greenlight Capital, Citadel LLC, LHC Capital, Prophecy Asset Management, Williams-Sonoma, Inc. (WSM), Palmer Square Capital (PSBD), and More (Insider Monkey)
Jan-19-24 01:05PM	Stay Ahead of the Game With ResMed (RMD) Q2 Earnings: Wall Street's Insights on Key Metrics (Zacks)
Jan-17-24 12:05PM	Here's Why Investors Should Retain ResMed (RMD) Stock for Now (Zacks)
09:45AM	Here's Why ResMed (RMD) is a Strong Growth Stock (Zacks)
Jan-16-24 07:56AM	ResMed says its masks to remain on market despite FDA classification (Reuters)
Jan-12-24 12:58AM	Resmeds magnetized masks linked to 6 patient injuries, FDA says (MedTech Dive)
Jan-11-24 05:50PM	US FDA identifies recall of ResMed's respiratory devices as most serious (Reuters)
Jan-03-24 04:05PM	ResMed to Report Second Quarter Fiscal 2024 Earnings on January 24, 2024 (GlobeNewswire)
Dec-27-23 04:05PM	ResMed Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-23 11:50PM	Resmed posts notice about risk of mask magnets interfering with medical implants (MedTech Dive)

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
De Witte Jan	Director	May 15 '24	Sale	218.29	360	78,584	7,519	May 17 11:27 AM
Sandercock Brett	Chief Financial Officer	May 08 '24	Option Exercise	101.64	12,000	1,219,680	105,056	May 10 03:21 PM
Sandercock Brett	Chief Financial Officer	May 08 '24	Sale	211.37	13,000	2,747,810	92,056	May 10 03:21 PM
Farrell Michael J.	Chief Executive Officer	May 07 '24	Option Exercise	84.98	14,683	1,247,761	455,435	May 09 11:58 AM
Farrell Michael J.	Chief Executive Officer	May 07 '24	Sale	216.50	14,683	3,178,815	440,752	May 09 11:58 AM
Drexler Karen	Director	Apr 29 '24	Sale	214.92	425	91,341	8,446	Apr 30 02:17 PM
Rider Michael J	Global General Counsel	Mar 04 '24	Sale	180.00	81	14,580	6,607	Mar 06 08:46 PM
Rider Michael J	Global General Counsel	Mar 01 '24	Sale	173.25	200	34,650	6,688	Mar 04 07:11 PM
FARRELL PETER C	Director	Feb 22 '24	Sale	182.66	10,935	1,997,434	157,404	Feb 23 06:40 PM
Sandercock Brett	Chief Financial Officer	Nov 27 '23	Sale	152.62	3,000	457,860	92,962	Nov 29 07:45 PM
Farrell Michael J.	Chief Executive Officer	Nov 15 '23	Option Exercise	57.76	5,678	327,961	446,664	Nov 16 09:20 PM
Farrell Michael J.	Chief Executive Officer	Nov 15 '23	Sale	152.04	5,678	863,281	440,986	Nov 16 09:20 PM
Rider Michael J	Global General Counsel	Nov 01 '23	Sale	143.42	25	3,585	7,358	Nov 02 09:29 PM
Farrell Michael J.	Chief Executive Officer	Oct 16 '23	Option Exercise	57.76	5,675	327,788	455,035	Oct 17 06:50 PM
Farrell Michael J.	Chief Executive Officer	Oct 16 '23	Sale	140.70	5,675	798,464	449,360	Oct 17 06:50 PM
Rider Michael J	Global General Counsel	Oct 02 '23	Sale	145.92	25	3,648	7,383	Oct 04 10:57 AM
Farrell Michael J.	Chief Executive Officer	Sep 15 '23	Option Exercise	57.76	5,675	327,788	455,035	Sep 19 02:54 PM
Farrell Michael J.	Chief Executive Officer	Sep 15 '23	Sale	146.35	5,675	830,514	449,360	Sep 19 02:54 PM
Rider Michael J	Global General Counsel	Sep 01 '23	Sale	161.15	25	4,029	7,408	Sep 07 03:44 PM
Farrell Michael J.	Chief Executive Officer	Aug 15 '23	Option Exercise	57.76	5,675	327,788	442,605	Aug 17 01:39 PM
Farrell Michael J.	Chief Executive Officer	Aug 15 '23	Sale	183.20	5,675	1,039,647	436,930	Aug 17 01:39 PM
Douglas Robert Andrew	President and COO	Aug 15 '23	Sale	181.01	1,500	271,515	250,526	Aug 16 01:51 PM
Rider Michael J	Global General Counsel	Aug 01 '23	Sale	224.12	25	5,603	5,186	Aug 02 05:30 PM
Farrell Michael J.	Chief Executive Officer	Jul 17 '23	Option Exercise	57.76	5,675	327,788	442,605	Jul 19 12:13 PM
Farrell Michael J.	Chief Executive Officer	Jul 17 '23	Sale	221.27	5,675	1,255,686	436,930	Jul 19 12:13 PM
Douglas Robert Andrew	President and COO	Jul 17 '23	Sale	222.22	1,500	333,330	252,026	Jul 18 05:02 PM
Ghoshal Kaushik	President, SaaS Business	Jul 13 '23	Sale	220.00	500	110,000	11,787	Jul 14 12:26 PM
Rider Michael J	Global General Counsel	Jul 03 '23	Sale	217.21	25	5,430	5,211	Jul 05 02:13 PM
Farrell Michael J.	Chief Executive Officer	Jun 15 '23	Option Exercise	57.76	5,675	327,788	442,605	Jun 16 05:17 PM
Farrell Michael J.	Chief Executive Officer	Jun 15 '23	Sale	217.39	5,675	1,233,716	436,930	Jun 16 05:17 PM
Douglas Robert Andrew	President and COO	Jun 15 '23	Sale	216.27	1,500	324,405	253,526	Jun 20 12:02 PM
PENDARVIS DAVID	Chief Administrative Officer	Jun 05 '23	Sale	219.79	1,500	329,685	89,729	Jun 07 12:20 PM
Ghoshal Kaushik	President, SaaS Business	Jun 02 '23	Sale	220.00	500	110,000	12,287	Jun 06 01:18 PM

Open in Screener

EOLS

Evolus Inc

May 21 • 11:22AM ET

13.28

Dollar change -0.14
Percentage change -1.04	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO VHT VTWO IWC PTH ITOT VFMO

Index	RUT	P/E	-	EPS (ttm)	-1.05	Insider Own	21.18%	Shs Outstand	57.82M	Perf Week	3.99%
Market Cap	831.46M	Forward P/E	143.57	EPS next Y	0.09	Insider Trans	-2.23%	Shs Float	53.75M	Perf Month	13.31%
Income	-60.00M	PEG	-	EPS next Q	-0.05	Inst Own	79.31%	Short Float	8.89%	Perf Quarter	1.61%
Sales	219.70M	P/S	3.78	EPS this Y	55.00%	Inst Trans	0.63%	Short Ratio	7.44	Perf Half Y	41.58%
Book/sh	0.30	P/B	44.84	EPS next Y	132.84%	ROA	-31.06%	Short Interest	4.78M	Perf Year	34.28%
Cash/sh	1.55	P/C	8.58	EPS next 5Y	16.50%	ROE	-472.61%	52W Range	7.07 - 15.43	Perf YTD	26.12%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.81%	ROI	-41.69%	52W High	-13.95%	Beta	1.33
Dividend TTM	-	Quick Ratio	2.96	Sales past 5Y	44.65%	Gross Margin	66.85%	52W Low	87.84%	ATR (14)	0.49
Dividend Ex-Date	-	Current Ratio	3.21	EPS Y/Y TTM	18.05%	Oper. Margin	-15.05%	RSI (14)	56.00	Volatility	3.45% 3.95%
Employees	273	Debt/Eq	6.87	Sales Y/Y TTM	40.45%	Profit Margin	-27.31%	Recom	1.12	Target Price	22.29
Option/Short	Yes / Yes	LT Debt/Eq	6.81	EPS Q/Q	14.85%	Payout	-	Rel Volume	0.22	Prev Close	13.42
Sales Surprise	3.61%	EPS Surprise	45.49%	Sales Q/Q	42.21%	Earnings	May 07 AMC	Avg Volume	642.52K	Price	13.28
SMA20	4.57%	SMA50	1.91%	SMA200	21.18%	Trades		Volume	46,478	Change	-1.04%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-24	Upgrade	Barclays	Equal Weight → Overweight	$10 → $16
Jun-23-22	Initiated	Needham	Buy	$18
May-12-22	Upgrade	Barclays	Underweight → Equal Weight	$8 → $10
Jan-20-22	Upgrade	Truist	Hold → Buy	$11
May-06-21	Upgrade	Mizuho	Neutral → Buy	$15
Apr-08-21	Reiterated	H.C. Wainwright	Buy	$20 → $22
Feb-24-21	Downgrade	Truist	Buy → Hold	$12
Jul-07-20	Downgrade	Mizuho	Buy → Neutral	$8 → $3
Feb-06-20	Resumed	Mizuho	Buy
Nov-26-19	Initiated	SVB Leerink	Outperform	$25
Sep-05-19	Resumed	Mizuho	Buy	$30
Jun-28-19	Initiated	Wells Fargo	Market Perform	$16
Jun-11-19	Initiated	Barclays	Underweight	$13
Mar-20-19	Initiated	SunTrust	Buy	$30
Feb-14-19	Initiated	H.C. Wainwright	Buy	$37
Jan-29-19	Initiated	Stifel	Buy	$27

Show Previous Ratings

May-20-24 08:30AM	Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse Dermal Filler Products at 2024 SCALE Meeting (Business Wire)
May-16-24 02:54AM	Director David Gill Sells 10,361 Shares of Evolus Inc (EOLS) (GuruFocus.com)
02:54AM	Director Vikram Malik Sells 28,000 Shares of Evolus Inc (EOLS) (GuruFocus.com)
May-15-24 08:30AM	Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau at the Women's Wear Daily Beauty CEO Summit (Business Wire)
May-10-24 06:55PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:10AM	Loading…
09:10AM	Evolus Sandra Beaver Named Orange County Business Journals Public Company CFO of the Year (Business Wire)
May-08-24 11:09AM	Evolus, Inc. (NASDAQ:EOLS) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:24AM	Q1 2024 Evolus Inc Earnings Call (Thomson Reuters StreetEvents)
03:53AM	Evolus Inc (EOLS) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth and Strategic ... (GuruFocus.com)
May-07-24 08:58PM	EOLS Stock Earnings: Evolus Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:35PM	Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:46PM	Evolus Inc (EOLS) Q1 2024 Earnings: Surpasses Revenue Estimates with Significant Growth (GuruFocus.com)
04:05PM	Evolus Reports First Quarter 2024 Results and Provides Business Update (Business Wire)
May-02-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
Apr-23-24 04:30PM	Evolus to Report First Quarter Financial Results on May 7, 2024 (Business Wire)
10:39AM	Loading…
Apr-21-24 10:39AM	11 Best Low Price Pharma Stocks To Invest In (Insider Monkey)
Apr-17-24 04:05PM	Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for Extra-Strength 40U Formulation of Jeuveau (Business Wire)
Apr-12-24 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-26-24 08:00AM	Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-14-24 07:04AM	10 Stocks George Soros and Insiders Are Crazy About (Insider Monkey)
Mar-13-24 09:55AM	Does Evolus, Inc. (EOLS) Have the Potential to Rally 63.24% as Wall Street Analysts Expect? (Zacks)
Mar-11-24 07:00AM	Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock (Business Wire)
Mar-08-24 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
03:24PM	Evolus, Inc. (NASDAQ:EOLS) Q4 2023 Earnings Call Transcript (Insider Monkey)
12:30PM	Q4 2023 Evolus Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-07-24 10:34PM	Evolus Inc (EOLS) Reports Record Revenues in Q4 and Full Year 2023, Eyes Profitability in 2024 (GuruFocus.com)
09:53PM	EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:05PM	Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance (Business Wire)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Mar-01-24 08:30AM	Evolus Announces Results from European Head-to-Head Filler Trial (Business Wire)
08:30AM	Loading…
Feb-27-24 08:30AM	Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences (Business Wire)
Feb-22-24 04:30PM	Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024 (Business Wire)
Feb-09-24 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-02-24 09:10PM	Evolus Inc Director Karah Parschauer Sells 11,931 Shares (GuruFocus.com)
Jan-16-24 05:28PM	Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance (Business Wire)
Jan-12-24 04:23PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-09-24 06:21PM	Wall Street Analysts See a 133.85% Upside in Evolus, Inc. (EOLS): Can the Stock Really Move This High? (Zacks)
Jan-04-24 04:05PM	Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications (Business Wire)
Dec-20-23 08:00AM	Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe (Business Wire)
Dec-08-23 04:30PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-13-23 09:08AM	Evolus, Inc. (NASDAQ:EOLS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 05:16PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-07-23 04:16PM	Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau (Business Wire)
Nov-06-23 08:45AM	Extra-Strength 40U Formulation of JeuveauDemonstrates Effects Lasting 26 Weeks in Phase II Data Presented at 2023 ASDS Annual Meeting (Business Wire)
Nov-01-23 08:45AM	Evolus to Participate in November Investor Conferences (Business Wire)
Oct-25-23 08:45AM	Final Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented at 2023 ASDS Annual Meeting (Business Wire)
08:45AM	Evolus to Report Third Quarter 2023 Results (Business Wire)
Oct-08-23 06:41PM	7 Must-Own Small-Cap Stocks That Could Outperform the Market (InvestorPlace)
Sep-29-23 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-13-23 04:10PM	7 Small-Cap Stocks Analysts Predict Will Double in 2024 (InvestorPlace)
Sep-09-23 01:03PM	Insider Sell: CFO Sandra Beaver Sells 3,178 Shares of Evolus Inc (EOLS) (GuruFocus.com)
Sep-03-23 05:29AM	12 Cheapest and Best Countries for Plastic Surgery (Insider Monkey)
Aug-29-23 08:45AM	Evolus to Participate in September Conferences (Business Wire)
Aug-27-23 07:20PM	Insiders Pour Millions Into These 2 Stocks, Analysts Say They Have up to 120% Upside Heres Why You Should Pay Attention (TipRanks)
Aug-23-23 06:53PM	Evolus Announces Inducement Grants for New Chief Marketing Officer (Business Wire)
Aug-21-23 08:45AM	Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer (Business Wire)
Aug-08-23 09:15AM	Stonegate Capital Partners Announces Publishing of a Thematic Report - Undervalued Growth Pharma Companies Amidst Healthcare Sector Decline (Newsfile)
08:45AM	Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers (Business Wire)
Aug-02-23 05:45PM	Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Evolus Reports Second Quarter 2023 Results and Provides Business Update (Business Wire)
Jul-27-23 11:42AM	Why Shares of Evolus Are Jumping Thursday (Motley Fool) +29.54%
08:45AM	Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue (Business Wire)
Jul-26-23 10:02AM	Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know (Zacks)
08:45AM	Evolus to Participate in Canaccord Genuitys 43rd Annual Growth Conference (Business Wire)
Jul-19-23 08:45AM	Evolus to Report Second Quarter 2023 Results and Provide Business Update (Business Wire)
Jul-15-23 07:30AM	Twitter Faces Threats From AI and Threads (Motley Fool)
Jun-29-23 09:00AM	Evolus Launches Nuceiva® (botulinum toxin type A) in Italy (Business Wire)
Jun-22-23 08:45AM	Evolus Announces Successful Completion of Phase 2 Study Evaluating "Extra-Strength" Dose of Jeuveau ® (Business Wire)
Jun-08-23 04:05PM	Evolus Reaches 1 Million Redemptions in its Evolus Rewards Patient Loyalty Program (Business Wire)
Jun-02-23 06:38AM	Positive Signs As Multiple Insiders Buy Evolus Stock \ (Simply Wall St.)
May-16-23 01:44PM	Evolus (NASDAQ:EOLS) rallies 16% this week, taking three-year gains to 161% (Simply Wall St.) -5.91%
May-09-23 05:25PM	Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Evolus Reports First Quarter 2023 Results and Provides Business Update (Business Wire)
04:01PM	Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse, a First-Generation Cold Technology HA by Symatese (Business Wire)
May-05-23 01:37PM	Evolus to Report First Quarter 2023 Results and Provide Business Update (Business Wire)
Apr-17-23 11:05AM	Evolus, Inc.'s (NASDAQ:EOLS) P/S Still Appears To Be Reasonable (Simply Wall St.)
Apr-04-23 10:39AM	Billionaire Israel Englander Goes Big on These 2 Strong Buy Stocks (TipRanks)
Mar-11-23 06:38AM	Evolus, Inc. (NASDAQ:EOLS) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-09-23 10:12AM	Q4 2022 Evolus Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-08-23 05:35PM	Evolus, Inc. (EOLS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update (Business Wire)
Feb-28-23 08:45AM	Evolus to Participate in the Barclays Global Healthcare Conference (Business Wire)
Feb-27-23 08:45AM	Evolus Initiates Nuceiva® Launch in Germany and Austria (Business Wire)
Feb-22-23 08:45AM	Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update (Business Wire)
Feb-10-23 11:07AM	Evolus Not Affected by Recent Korean Court Ruling (Business Wire)
Jan-31-23 08:45AM	Evolus to Participate in the SVB Securities Global Biopharma Conference (Business Wire) +5.80%
Jan-30-23 12:02PM	Institutional investors own a significant stake of 39% in Evolus, Inc. (NASDAQ:EOLS) (Simply Wall St.)
07:09AM	Evolus Says 'Extra Strength' Jeuveau Shows A Durable Effect In Frown Lines (Benzinga)
Jan-28-23 08:00AM	"Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6-Month Performance (Business Wire)
Jan-23-23 09:00AM	Evolus Receives Regulatory Approval for Nuceiva® in Australia (Business Wire)
08:00AM	Evolus to Present Phase 2 Interim Data from Jeuveau® "Extra-Strength" Dose for Extended Duration Study at 2023 IMCAS World Congress (Business Wire)
Jan-20-23 01:54PM	Why Evolus Shares Jumped This Week (Motley Fool) +5.04%
Jan-19-23 01:15PM	Here's Why This Analyst Seems Highly Convinced With Evolus' Outlook (Benzinga) +5.31%
Jan-18-23 08:45AM	Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration (Business Wire) +18.09%
Jan-03-23 10:03AM	Evolus, Inc.'s (NASDAQ:EOLS) Shift From Loss To Profit (Simply Wall St.)
Dec-08-22 08:45AM	Evolus Extends Term of Credit Facility with Pharmakon Advisors (Business Wire) +7.65%
Dec-07-22 10:00AM	Leading MedTech marketplace Pipeline Medical now provides Jeuveau® by Evolus, Inc. (PR Newswire)
09:17AM	Shareholders in Evolus (NASDAQ:EOLS) are in the red if they invested three years ago (Simply Wall St.)
Nov-10-22 05:57AM	Evolus Third Quarter 2022 Earnings: Revenues Disappoint (Simply Wall St.) +6.08%
Nov-08-22 06:25PM	Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GILL DAVID N	Director	May 14 '24	Sale	12.60	6,718	84,654	33,964	May 15 05:20 PM
Malik Vikram	Director	May 13 '24	Sale	12.93	28,000	362,012	254,014	May 15 05:19 PM
GILL DAVID N	Director	May 13 '24	Sale	12.72	3,643	46,356	40,682	May 15 05:20 PM
MOATAZEDI DAVID	See Remarks	May 10 '24	Sale	12.72	16,051	204,127	673,563	May 14 08:56 PM
Avelar Rui	See Remarks	May 10 '24	Sale	12.72	3,441	43,761	368,847	May 14 08:56 PM
Beaver Sandra	Chief Financial Officer	May 10 '24	Sale	12.72	2,423	30,814	151,778	May 14 08:55 PM
MOATAZEDI DAVID	See Remarks	Mar 27 '24	Sale	13.86	6,236	86,431	689,614	Mar 29 07:08 PM
MOATAZEDI DAVID	See Remarks	Mar 19 '24	Sale	13.92	96,566	1,344,604	695,850	Mar 21 06:08 PM
Avelar Rui	See Remarks	Mar 19 '24	Sale	13.92	27,603	384,350	372,288	Mar 21 06:09 PM
Beaver Sandra	Chief Financial Officer	Mar 19 '24	Sale	13.92	5,672	78,978	154,201	Mar 21 06:09 PM
MOATAZEDI DAVID	See Remarks	Feb 22 '24	Sale	13.08	7,706	100,804	792,416	Feb 23 08:27 PM
Beaver Sandra	Chief Financial Officer	Feb 22 '24	Sale	13.08	1,821	23,821	159,873	Feb 23 08:27 PM
Avelar Rui	See Remarks	Feb 22 '24	Sale	13.08	1,821	23,821	399,891	Feb 23 08:27 PM
Parschauer Karah Herdman	Director	Jan 30 '24	Sale	13.14	11,931	156,733	31,243	Feb 02 04:57 PM
MOATAZEDI DAVID	See Remarks	Dec 08 '23	Sale	9.73	31,300	304,505	603,944	Dec 08 06:15 PM
MOATAZEDI DAVID	See Remarks	Dec 06 '23	Sale	10.09	51,348	517,891	635,244	Dec 08 06:15 PM
Medytox Inc.	Former 10% Owner	Oct 16 '23	Sale	7.50	1,690,663	12,679,972	3,381,326	Oct 18 04:21 PM
Beaver Sandra	Chief Financial Officer	Sep 06 '23	Sale	9.70	3,178	30,827	113,368	Sep 08 08:54 PM
MOATAZEDI DAVID	See Remarks	Aug 16 '23	Sale	10.27	14,778	151,770	686,592	Aug 16 08:25 PM
Beaver Sandra	Chief Financial Officer	Aug 16 '23	Sale	10.27	2,211	22,707	116,546	Aug 16 08:25 PM
Avelar Rui	See Remarks	Aug 16 '23	Sale	10.27	2,211	22,707	353,386	Aug 16 08:25 PM
Malik Vikram	Director	Aug 15 '23	Buy	7.41	174,967	1,296,505	275,550	Aug 15 04:34 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

RMD

Resmed Inc.

EOLS

Evolus Inc

Upgrade your FINVIZ experience